Ordering
Available Variants10 mg
CHA.23913-10mg
Price
€63.68
Available – Dispatch in 14 days
50 mg
CHA.23913-50mg
Price
€254.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.23913-10mg | €63.68 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.23913-50mg | €254.40 |
analytical standard, (E) and (Z) isomers (50:50)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C26H29NO2 |
|---|---|
| CAS Number | 68392-35-8 |
| Molecular Weight | 387.51 |
| UNSPSC Code | 41116107 |
| PubChem Substance ID | 24899989 |
| NACRES | NA.24 |
Safety Information Handling visibility
| pictograms |
GHS08
GHS07
  GHS08,GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302 + H312 + H332,H315,H319,H361fd |
| pcodes | P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 - P305 + P351 + P338 - P308 + P313 |
| Hazard Classifications | Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Gloves, type P3 (EN 143) respirator cartridges |
Technical Overview & Applications Use-case context
4-Hydroxytamoxifen, with the CAS number 68392-35-8, is a metabolite of the selective estrogen receptor modulator tamoxifen. It is primarily formed through the hepatic metabolism of tamoxifen, mediated by the cytochrome P450 enzyme system. As a result of this biotransformation, 4-hydroxytamoxifen exhibits a higher affinity for estrogen receptors compared to its parent compound, thereby contributing to the therapeutic efficacy of tamoxifen in the treatment of hormone receptor-positive breast cancer. The compounds increased potency is attributed to its ability to bind more effectively to estrogen receptors, leading to a more pronounced anti-estrogenic effect. This metabolite plays a crucial role in the pharmacological activity of tamoxifen, and its formation is a key factor in determining the drugs overall clinical effectiveness. The study of 4-hydroxytamoxifen has provided valuable insights into the mechanisms of tamoxifen action.
